Methotrexate and relative risk of dementia amongst patients with Rheumatoid Arthritis: a multi-national multi-database case-control study
Abstract Inflammatory processes have been shown to play a role in dementia. To understand this role we selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia risk.METHODS A retrospective matched case-control study, of patients over 50 with rheumatoid arthritis (486 dementia cases and 641 controls) were identified from electronic health records in the United Kingdom, Spain, Denmark and the Netherlands. Conditional logistic regression models were fitted to estimate risk of dementia.RESULTS Prior methotrexate use was associated with dementia (OR: 0.71 95% CI 0.52-0.98). Methotrexate use was strongest with therapy longer than 4 years (odds ratio: 0.37 95% CI 0.17-0.79). Sulfasalazine use was not associated with dementia (odds ratio: 0.88 95% CI 0.57-1.37).CONCLUSIONS Further studies are still required to clarify the relationship between prior methotrexate use and duration as well as biological treatments with dementia risk.